Vortex Biosciences PLC's CEO Paul Jones explains the company's technology for capturing live circulating tumour cells (CTCs).
One of NetScientific PLC (AIM:NSCI)'s portfolio companies, Jones says the next stage for developing the business is to build relationships with the pharmas and biotechs developing cancer therapies and support them with companion diagnostics.
This will involve Vortex moving towards a CTC service providing lab-developed tests and in-vitro diagnostics, he says.
#Vortex Biosciences #Netscientific